GHGuardant Health, Inc.
Price
+183%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, growing in the filings, the market undecided.
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Guardant Health, Inc. (GH) reported revenue of $335M in Q2 2026 (quarter ended Jun 30, 2026), up 44% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $120M. For the full year FY2025, revenue was $982M (+33% year on year) and net income −$416M. Its largest product in Q2 2026 was Oncology at $219M, 65% of the disclosed total, well ahead of Biopharma Data at 18%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance.Earnings release · press release
- May 7, 2026Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance.Earnings release · press release
- Apr 27, 2026On April 27, 2026, Guardant Health, Inc. (the “Company”) announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer, to be effective as of May 8, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $335.0MThe company’s own SEC segment disclosure.
- Oncology$219.1M65%
- Biopharma Data$60.9M18%
- Screening$52.9M16%
- Licensing Other$2.1M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #18 of 21 by RyuScore